OMCL Add to watchlist
$37.53 +1.20 (+3.30%)
After Hours: $37.53 +0.00 (+0.00%)
Last updated: Apr 15, 2026 22:59
52-Week Range
$37.53
$22.66 $37.53 $55.00

Fundamentals Overview

Omnicell, Inc. is in the middle of its 52-week range with premium valuation, trending upward today.

Valuation premium

P/E 822.3 P/B 1.37 P/S 1.44

Intrinsic value (DCF)

-9.4% downside vs price

Profitability

Net margin 0.2%

Risk (Beta)

0.86 — in line vol

Earnings & growth

EPS $0.05 Rev +1.1% Profit -137.1% vs prior qtr

BullzEye Analysis

Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell
Buy
Hold — 52% confidence Risk: Moderate Volatility — Beta 0.86. Diversify and only invest what you can afford to lose.

Supporting (Buy):

Analyst grade: B+ · Sentiment improving (2 upgrades)

Pressures (Sell):

3M vs S&P 500: -27.4% · 3M vs Healthcare sector: -20.6%

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap
$1.71B
P/E (TTM)
822.28
EPS (TTM)
$0.05
Dividend Yield
N/A
52-Week Range
$22.66 - $55.00
Volume vs Avg
N/A
Beta
0.86

About

Omnicell, Inc., together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing syste...
Sector: Healthcare
Headquarters: US
Employees: 3,620
IPO Date: Aug 2001
Beta: 0.86 (Less volatile than market)

Ratings & Grades at a Glance

Overall rating: B+. Recent institutional grades: majority upgrades. Current institutional positions: Buy: 8, Equal Weight: 5, Neutral: 10, Overweight: 7.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $34.02; current price is $37.53. That’s a -9.4% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric Value
Valuation
P/E (TTM) 822.28
DCF value (model) $34.02 (-9.4% vs price)
PEG (TTM) N/A
P/B (TTM) 1.37
P/S (TTM) 1.44
P/FCF (TTM) 20.19
Liquidity & enterprise
Current Ratio (TTM) 1.43
Quick Ratio (TTM) 1.22
Cash Ratio (TTM) 0.41
Profitability
ROE (TTM) N/A
ROA (TTM) N/A
Revenue growth (YoY) N/A
Net margin (TTM) 0.17%
Gross margin (TTM) 42.49%
Operating margin (TTM) 0.44%
Debt to equity (TTM) N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for OMCL.

Analyst Sentiment at a Glance

B+ Sentiment Improving
Buy 8Equal Weight 5Neutral 10Overweight 7
2 upgrades, 1 downgrade
Price Target Consensus
Current $37.53
Median $56.00
Consensus $55.25
Low consensus $49.00
High consensus $60.00

Stock Grades (Institutions)

Institution Action Previous Grade New Grade Date
Piper Sandler maintain Overweight Overweight 2026-02-06
Benchmark maintain Buy Buy 2026-02-02
Keybanc upgrade Sector Weight Overweight 2026-01-08
Wells Fargo maintain Overweight Overweight 2026-01-05
Benchmark maintain Buy Buy 2025-12-09
B of A Securities maintain Neutral Neutral 2025-12-09
Benchmark maintain Buy Buy 2025-10-31
Piper Sandler maintain Overweight Overweight 2025-08-11
Wells Fargo maintain Overweight Overweight 2025-07-21
B of A Securities maintain Neutral Neutral 2025-07-14
B of A Securities maintain Neutral Neutral 2025-05-23
Wells Fargo maintain Overweight Overweight 2025-05-23
Wells Fargo upgrade Equal Weight Overweight 2025-05-14
Wells Fargo maintain Equal Weight Equal Weight 2025-05-07
B of A Securities maintain Neutral Neutral 2025-05-07
Benchmark maintain Buy Buy 2025-05-07
Wells Fargo maintain Equal Weight Equal Weight 2025-04-17
JP Morgan maintain Neutral Neutral 2025-03-20
B of A Securities maintain Neutral Neutral 2025-03-13
Benchmark maintain Buy Buy 2025-02-04
Wells Fargo maintain Equal Weight Equal Weight 2025-01-13
B of A Securities maintain Neutral Neutral 2025-01-06
JP Morgan maintain Neutral Neutral 2024-11-21
Barclays maintain Equal Weight Equal Weight 2024-10-31
Craig-Hallum maintain Buy Buy 2024-10-31
B of A Securities downgrade Buy Neutral 2024-10-31
Wells Fargo maintain Equal Weight Equal Weight 2024-10-14
Benchmark maintain Buy Buy 2024-10-09
JP Morgan maintain Neutral Neutral 2024-08-23
B of A Securities maintain Buy Buy 2024-08-02